penn medicine
penn surgery
penn surgery home penn surgery clinical penn surgery education penn surgery research penn surgery administration

Brian J. Czerniecki, M.D., Ph.D.
Endocrine and Oncologic Surgery

 
  • Profile Home
  • Appointments
  • Education
  • Memberships
  • Research
  • Publications

Administrative & Clinical Office:
Perelman Center for Advanced Medicine
Rena Rowan Breast Center
Abramson Cancer Center
3rd Floor West
3400 Civic Center Boulevard
Philadelphia, PA 19104
Administrative Assistant: Patricia Rahill
Administrative Telephone: 215-662-4392
Administrative Fax: 215-615-0555
Patient Appointments: 215-615-5858

Contact Information (internal use only)

brian.czerniecki@uphs.upenn.edu

 

Brian J. Czerniecki, MD, PhD is the Rhodes-Harrington Professor in Surgical Oncology at the University of Pennsylvania and the Co-Director of the Rena Rowan Breast Center.  His research interests focus on dendritic cell biology and interactions with T cells. He has developed dendritic cell vaccines for the treatment of cancer and is involved with several clinical trials for treating patients with early breast cancer with dendritic cell vaccines.  The overall goal is develop vaccines for the prevention of breast cancer and other solid tumors. He is identifying molecular targets in early breast cancer that can be used for prevention of invasion and metastasis. Dr. Czerniecki received his BS in Biochemistry from the University of Maine and MD, PhD from UMDNJ-Robert Wood Johnson and Rutgers University. He completed his general surgical residency at The Ohio State University and was Surgical Oncology Fellow at the NCI with Dr. Steven Rosenberg prior to his position at the University of Pennsylvania.

 
Faculty Appointments
1989 - 1993 Clinical Instructor, Department of Surgery
Ohio State University, Columbus, Ohio
 
1995 - 2004 Assistant Professor of Surgery
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
 
2004 - 2012 Associate Professor of Surgery at HUP
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
 
2005 - present Member Graduate Group in Immunology
 
2007 - present Program Director
PENN Breast Fellowship Program
   
2012 - present Professor of Surgery at HUP
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
 
Hospital and Administrative Appointments
1995 - present Attending Surgeon, Department of Surgery
Hospital of the University of University of Pennsylvania Philadelphia, Pennsylvania
 
1998 - 2001 Active Surgeon, Presbyterian Medical Center Philadelphia, Pennsylvania
 
2007 - present Co-Director Rena Rowan Breast Center
 
2007 - present Surgical Director of Immunotherapy ACC
 
2008 - present SSO Breast Program Directors Committee
 
2009 - present Chair of the Data Safety Monitoring Committee ACC
 
Education/Training
1978 - 1982 B.S. University of Maine (Biochemistry)
 
1982 - 1988 M.D. University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School
 
1984 - 1988 Ph.D. Rutgers University/UMDNJ/RWJMS
 
Postgraduate Training and Fellowship Appointments
1988 - 1989 Intern in Surgery, Ohio State University Hospital Columbus, Ohio
 
1989 - 1993 Resident in General Surgery
Ohio State University Hospital, Columbus, Ohio
 
1993 - 1995 Fellowship, Surgical Oncology
National Cancer Institute, Bethesda, Maryland
 
Military Service
1993 - 1995 U.S. Public Health Service, Lt. Commander
National Institutes of Health, Bethesda, Maryland
 
Memberships/Societies
 
National Societies
  • American Society of Breast Surgeons
  • American Association for Cancer Research
  • American Association of Immunologists
  • American College of Surgeons
  • American Society of Breast Diseases
  • American Society of Clinical Oncology
  • International Society of Biologic Therapy
  • Robert M. Zollinger Society
  • Society of Surgical Oncology
  • Society of University Surgeons
  • American College of Surgeons Oncology Group
  • Society for Academic Surgeons
  • International Society for Dendritic Cell and Vaccine Science
  • Alliance Cooperative Group – Prevention Committee Member
Local Societies
  • American College of Surgeons, Philadelphia Chapter
National and Local Scientific Committees
  • International Working Group, Breast MRI (1998-2003)
 
Research Research Laboratory
 
Dr. Czerniecki has tested with great success a cancer vaccine for patients with early stage breast cancer. The study, which is ongoing, sheds new light on how vaccines can inhibit tumor growth, lessen the severity of the disease, and prevent its recurrence. His team investigated a potential vaccine that targets HER-2/neu over-expression in early stage breast cancer (DCIS). Over-expression of the HER-2/neu gene is linked to about 50 to 60 percent of DCIS cases, and helps predict the severity of the disease, as well as the risk of recurrence of invasive breast cancer.

By treating dendritic cells – specialized white blood cells that play a major role in activating immune response – with HER-2/neu, Dr. Czerniecki produced a vaccine he hoped would prompt an immune response. In fact, researchers found that nearly all patients exhibited an initial immune reaction to the vaccine, and half showed markedly reduced levels of HER-2/neu expression, leading to overall improvement in the severity of the disease.

Featured on the March 2007 cover of Cancer Research, this study is a source of excitement and optimism in the medical community. According to Dr. Czerniecki, these “vaccination strategies may therefore have potential for both the prevention and treatment of early breast cancer.”

 
Publications
 
Research Publications, peer reviewed
  1. Czerniecki B. Gad SC. Reilly C. Smith AC. Witz G. Phorbol diacetate inhibits superoxide anion radical production and tumor promotion by mezerein. Carcinogenesis. 7(10):1637-1641, Oct. 1986.
  2. Czerniecki B. Witz G. Reilly C. Gad SC. The development of contact hypersensitivity in mouse skin is suppressed by tumor promoters. Journal of Applied Toxicology. 8(1):1-8, Feb. 1988.
  3. Ryer-Powder JE. Amoruso MA. Czerniecki B. Witz G. Goldstein BD. Inhalation of ozone produces a decrease in superoxide anion radical production in mouse alveolar macrophages. American Review of Respiratory Disease. 138(5):1129-1133, Nov. 1988.
  4. Witz G. Czerniecki BJ. Tumor promoters differ in their ability to stimulate superoxide anion radical production by murine peritoneal exudate cells following in vivo administration. Carcinogenesis. 10(5):807-811, May 1989.
  5. Goldstein BD. Czerniecki B. Witz G. The role of free radicals in tumor promotion. Environmental Health Perspectives. 81:55-57, May 1989.
  6. Czerniecki BJ. Witz G. Arachidonic acid potentiates superoxide anion radical production by murine peritoneal macrophages stimulated with tumor promoters. Carcinogenesis. 10(10):1769-1775, Oct. 1989.
  7. Czerniecki BJ. Witz G. Tumor promoters stimulate the formation of 1,2-diacylglycerol in murine peritoneal macrophages: a possible mechanism for stimulating superoxide anion radical production. Cancer Letters. 48(1):29-36, Nov. 15, 1989.
  8. Czerniecki BJ. Carter C. Rivoltini L. Koski GK. Kim HI. Weng DE. Roros JG. Hijazi YM. Xu S. Rosenberg SA. Cohen PA. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. Journal of Immunology. 159(8):3823-3837, Oct. 15, 1997.
  9. Czerniecki BJ. Scheff AM. Callans LS. Spitz FR. Bedrosian I. Conant EF. Orel SG. Berlin J. Helsabeck C. Fraker DL. Reynolds C. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer. 85(5):1098-1103, Mar. 1, 1999.
  10. Reynolds C. Mick R. Donohue JH. Grant CS. Farley DR. Callans LS. Orel SG. Keeney GL. Lawton TJ. Czerniecki BJ. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer?. Journal of Clinical Oncology. 17(6):1720-1726, June 1999.
  11. Bedrosian I. Scheff AM. Mick R. Callans LS. Bucky LP. Spitz FR. Helsabeck C. Elder DE. Alavi A. Fraker DF. Czerniecki BJ. 99mTc-human serum albumin: An effective radiotracer for identi-fying sentinel lymph nodes in melanoma. Journal of Nuclear Medicine. 40(7):1143-1148, July 1999.
  12. Koski GK. Schwartz GN. Weng DE. Czerniecki BJ. Carter C. Gress RE. Cohen PA. Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like charac-teristics through discrete signaling pathways. Journal of Immunology. 163(1):82-92, July 1, 1999.
  13. Koski GK. Schwartz GN. Weng DE. Gress RE. Engels FH. Tsokos M. Czerniecki BJ. Cohen PA. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood. 94(4):1359-1371, Aug. 15, 1999.
  14. Engels FH. Koski GK. Bedrosian I. Xu S. Luger S. Nowell PC. Cohen PA. Czerniecki BJ. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proceedings of the National Academy of Sciences of the United States of America. 96(18):10332-10337, Aug. 31, 1999.
  15. Weinstein S. Zuckerman J. Lawton T. Orel S. Czerniecki BJ. Conant E. Retrospective review of palpable breast lesions after negative mammography and sonography. Journal of Women's Imaging 2:15-18, 2000.
  16. Faries MB. Bedrosian I. Reynolds C. Nguyen HQ. Alavi A. Czerniecki BJ. Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status. Annals of Surgical Oncology. 7(2):98-105, Mar. 2000.
  17. Bedrosian I. Faries MB. Guerry D 4th. Elenitsas R. Schuchter L. Mick R. Spitz FR. Bucky LP. Alavi A. Elder DE. Fraker DL. Czerniecki BJ. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Annals of Surgical Oncology. 7(4):262-7, May 2000.
  18. Bedrosian I. Roros JG. Xu S. Nguyen HQ. Engels F. Faries MB. Koski GK. Cohen PA. Czerniecki BJ. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function. Journal of Immunotherapy. 23(3):311-20, May/June 2000.
  19. Bedrosian I. Reynolds C. Mick R. Callans LS. Grant CS. Donohue JH. Farley DR. Heller R. Conant E. Orel SG. Lawton T. Fraker DL. Czerniecki BJ. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 88(11):2540-2545, June 1, 2000.
  20. Orel SG. Dougherty CS. Reynolds C. Czerniecki BJ. Siegelman ES. Schnall MD. MR imaging in patients with nipple discharge: initial experience. Radiology. 216(1):248-254, July 2000.
  21. Engels FH. Kreisel D. Faries MB. Bedrosian I. Koski GK. Cohen PA. Czerniecki BJ. Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase. Leukemia Research. 24(10):795-804, Oct. 2000.
  22. Weinstein SP. Orel SG. Heller R. Reynolds C. Czerniecki B. Solin LJ. Schnall M. MR imaging of the breast in patients with invasive lobular carcinoma. AJR. American Journal of Roentgenology. 176(2):399-406, Feb. 2001.
  23. Chang JH. Vines E. Bertsch H. Fraker DL. Czerniecki BJ. Rosato EF. Lawton T. Conant EF. Orel SG. Schuchter L. Fox KR. Zieber N. Glick JH. Solin LJ. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 91(7):1231-1237, Apr. 1, 2001.
  24. Czerniecki BJ. Cohen PA. Faries M. Xu S. Roros JG. Bedrosian I. Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Critical Reviews in Immunology 21(1-3):157-178, 2001.
  25. Cohen PA. Peng L. Kjaergaard J. Plautz GE. Finke JH. Koski GK. Czerniecki BJ. Shu S. T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance. Critical Reviews in Immunology 21(1-3):215-248, 2001.
  26. Czerniecki BJ. Bedrosian I. Faries M. Alavi A. Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology. Seminars in Nuclear Medicine 31(2):158-164, Apr. 2001.
  27. Wildemore JK 4th. Schuchter L. Mick R. Synnestvedt M. Elenitsas R. Bedrosian I. Czerniecki BJ. Guerry D 4th. Lessin SR. Elder DE. Bucky LP. Locally recurrent malignant melanoma characteristics and outcomes: A single-institution study. Annals of Plastic Surgery 46(5):488-494, May 2001.
  28. Weinstein SP. Orel SG. Collazzo L. Conant EF. Lawton TJ. Czerniecki B. Cyclosporin A-induced fibroadenomas of the breast: Report of five cases. Radiology 220(2):465-468, Aug. 2001.
  29. Faries MB. Bedrosian I. Xu S. Koski G. Roros JG. Moise MA. Nguyen HQ. Engels FH. Cohen PA. Czerniecki BJ. Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development. Blood 98(8):2489-2497, Oct. 15, 2001.
  30. Bauer TW. Spitz FR. Callans LS. Alavi A. Mick R. Weinstein SP. Bedrosian I. Fraker DL. Bauer TL. Czerniecki BJ. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Annals of Surgical Oncology 9(2):169-176, Mar. 2002.
  31. Prabakaran I. Menon C. Xu S. Gomez-Yafal A. Czerniecki BJ. Fraker DL. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells. Annals of Surgical Oncology 9(4):411-418, May 2002.
  32. Bedrosian I. Schlencker J. Spitz FR. Orel SG. Fraker DL. Callans LS. Schnall M. Reynolds C. Czerniecki BJ. Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Annals of Surgical Oncology 9(5):457-461, June 2002.
  33. Lee SG. Orel SG. Woo IJ. Cruz-Jove E. Putt ME. Solin LJ. Czerniecki BJ. Schnall MD. MR imaging screening of contralateral breast in patients with newly diagnosed breast cancer: Preliminary results. Radiology 226(3):773-778, Mar. 2003.
  34. Bedrosian I, Schlencker J, Mick R, Orel S, Schnall M, Reynolds C, Spitz FR, Callans L, Buzby GP, Rosato EF, Fraker DL, Czerniecki BJ. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 98(3):468-473, Aug. 1, 2003.
  35. Xu S, Koski GK, Faries MB, Bedrosian I, Mick R, Maeurer M, Chever, Cohen PA, Czerniecki BJ. Rapid high efficiency sensitization of CD8 + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL- 12 dependent mechanism. Journal of Immunology 171(5):2251-2261, Sept. 1, 2003.
  36. Bedrosian IB, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T cell function in melanoma patients. Journal of Clinical Oncology 21(20):3826-3835, Oct. 15, 2003.
  37. Koski GK, Kariko K, Xu S, Weissman D, Cohen PA, Czerniecki BJ, Cutting Edge: Innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. The Journal of Immunology, 2004, 172: 3989-3993, 2004.
  38. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xiaowei Xu, Czerniecki B, Spitz F, Schucter L, Elder, D. Thin primary cutaneous malignant melanoma: A prognostic tree for ten metastasis is more accurate than AJCC staging. Journal of Clinical Oncology 2004, 22: 3668-3676.
  39. Kesmodel SB, Karakousis GC, Botbyl, JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi, A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz, FR. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanoma. Annals of Surgical Oncology 12: 449-458 2005.
  40. Bedrosian, I. Czerniecki BJ. Change in surgical Management of breast cancer patients based on preoperative MR imaging Am J Onc Rev, 2004; 3(4):209.
  41. Downes K, Glatt BS, Kanchwala SK, Mick R, Fraker DL, Fox KR, Solin LJ, Bucky LP, Czerniecki BJ. Skin-sparing mastectomy and immediate reconstruction as an acceptable treatment option for high-risk breast cancer patients. Cancer 2005.
  42. Koski, GK, and Czerniecki BJ. Combining innate immunity with radiation therapy for cancer treatment. Clinical Can Res. 2005, 11: 7-11.
  43. Chance B, Nioka S, Zhang J, Conant EF, Hwang E, Briest SG, Orel SG, Schnall MD, Czerniecki BJ. Breast Cancer Detection based on incremental biochemical and physiological properties of breast cancers a six-year, two-site study. Acad Radiol 2005; 12(8):925-933.
  44. Choe R, Corlu A, Lee K, Durduran T, Konecky SD, Grosicka-Koptyra M, Arridge S, Czerniecki BJ, Fraker DL, DeMichele A, Chance B, Rosen M, Yodh A. Diffuse optical Tomography of breast cancer during neoadjuvant chemotherapy: a case study in comparison to MRI. Medical Physics 32:1128-1139 2005.
  45. Faries MB, Czerniecki BJ. Dendritic Cells in Melanoma Immunotherapy Current Treatment Options in Oncology 6(3): 175-84, 2005.
  46. Durduran, T, Choe R, Yu, G, Zhou C, Tchou, J, Czerniecki BJ, Yodh, A. Diffuse optical measurement of blood flow in breast tumors. Optics Letters 2005, 30:2915-2917.
  47. Jackson BM, Kim S, Davidson R, Schuchter L, Acs G, Czerniecki BJ. Re-operative sentinel lymph node biopsy: a case report. Clinical Breast Cancer 6: 530-532 2006.
  48. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, VanBelle P, Hotz, Elder DE, Marincola FM, Schuchter, L, Guerry D, Czerniecki BJ, Herlyn D. HLA-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res. 2006; 66:3287-3293.
  49. Karakousis GC, Gimotty PA, Botbyl, Kesmodel SB, Elder DE, Ming ME, Guerry D, Fraker DL, Czerniecki BJ, Spitz FR. Predictors of regional nodal disease in patients with thin melanomas. Annals of Surgical Oncology 13: 533-541 2006.
  50. Kesmodel SB, Canter RJ, Terhune KP, Bauer TW, Mick R, Rosato EF, Spitz FR, Fraker DL, Alavi A, Czerniecki BJ. Use of radiotracer for sentinel lymph node mapping in breast cancer optimizes staging independent of site of administration. Clinical Nuclear Medicine 31:1-7 2006.
  51. Xu S, Koldovsky U, Xu M, Wang D, Fitzpatrick E, Son G, Koski G, Czerniecki BJ. Toll receptor 8 signaling primes myeloid dendritic cells for high level IL-12 production. Surgery 140:170-178 2006.
  52. Gimotty, PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D. Identification of high-risk patients among those diagnosed with thin cutaneous melanoma. J. Clin. Oncol 25:1129-1134 2007.
  53. Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, Czerniecki B, Schnall M, Alavi A. Dual time point FDG-PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes of the lesions. J. Nuclear Medicine 47: 1440-1446 2006.
  54. Kruper LL, Spitz F, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME, Elder DE, Elenitsas R, Guerry D, Gimotty P. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 107:2436-2445 2006.
  55. Zhang T, Somasundarum R, Caputo, L, VanBelle P, Elder D, Czerniecki B, Hotz S, Schuchter L, Spitz FR, Klara B, Rani P, Marincola F, Qiu R, Herlyn D. Preferential Involvement of CX Chemokine Receptor 4 and CX Chemokine Ligand 12 in T-cell migration toward melanoma cells. Cancer Biology & Therapy (In Press).
  56. Czerniecki BJ, Xu M, Koski G. Neoadjuvant Therapy for HER-2/neu-expressing ductal carcinoma in situ using type 1 polarized dendritic cell vaccines. Breast Diseases: A Yearbook Quarterly 17: 320-323 2007.
  57. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged IL-12 burst secretion. Cancer Res 67:1842-1853 2007.
  58. Karakousis GC, Gimotty PA, Czerniecki BJ, Elder DE, Elenitsas R, Ming ME, Fraker DL, Guerry D, Spitz FR. Regional nodal metastatic disease is the strongest predictor of survival inpatients with thin vertical growth phase melanomas: A case for SLN staging biopsy in these patients. Ann Surg Oncol 14: 1596-1603 2007.
  59. Roses R, Xu M, Xu S, Koldovsky U, Son G, Koski GK, Czerniecki BJ. Working towards the development of cancer vaccines for the treatment and prevention of early breast cancer. Current Cancer Therapy Reviews 3:97-107 2007.
  60. Czerniecki BJ, Roses R, Koski GK. Development of vaccines for high risk ductal carcinoma in situ of the breast. Cancer Res 67: 6531-6534 2007.
  61. Vapiwala N, Starzyk J, Harris EE, Tchou JC, Boraas M, Czerniecki BJ, Rosato EF, Orel SG, Solin LJ. Biopsy findings following breast conservation therapy for early stage invasive breast cancer. Int. J. of Radiation Oncology Biology Physics (In Press).
  62. Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Jian YQ, Zhuang H, Czerniecki B, Alavi A. The effects of estrogen, progesterone, and c-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J. Nuclear Med. 48:1266-1272 2007.
  63. Roses R, Xu M, Koski GK, Czerniecki BJ. Radiation therapy and toll-like receptor signaling: implications for the treatment of cancer. Oncogene 27:200-207 2008.
  64. Koski GK, Roses R, Xu S, Cohen PA, Czerniecki BJ. Re-engineering dendritic cell-based anti-cancer vaccines. Immunologic Reviews 222: 256-276 2008.
  65. Cohen PA, Koski GK, Czerniecki BJ, Bunting K, Fu XY, Wang Z, Zhang WJ, Carter C, Awad M, Distel CA, Hassen N, Paustian C, Johnson T, Tisdale JF, Shu S. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34 positive cells into tumor-competent dendritic cells. Blood 112: 1832-1843 2008.
  66. Tchou J, Greshock J, Bergey M, Sonnad SS, Sargen M, Weinstein S, Czerniecki B, Boraas M, Fraker DL, Rosato E, Fox K, Weber B, Solin LJ. Method of primary tumor detection as a risk factor for local and distant recurrence after breast conservation treatment for early stage breast cancer. Clinical Breast Cancer 8: 2 2008.
  67. Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. Differential production of interleukin-23 and interleukin-12 by myeloid derived dendritic cells in response to toll-like receptor agonists. J Immunol 181:5120-5127 2008.
  68. Sharma A, Czerniecki BJ. Utilizing Genetic Phenotypes and Cancer Stem Cells as Novel Targets for Breast Cancer Vaccine Development. Current Medical Literature Breast Cancer 20 (3) 61-67, 2008.
  69. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Barbiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clinical Oncology 27 1-10, 2008.
  70. Choe, R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, Pathak S, Czerniecki BJ, Tchou J, Fraker DL, DeMichele A, Chance B, Arridge SR, Schweiger M, Culver JP, Schnall MD, Putt ME, Rosen MA,Yodh AG. Differentiation of benign and malignant breast tumors by in vivo three dimensional parallel-plate diffuse optical tomography. Journal of Biomedical Optics 14: 2009.
  71. Roses RE, Paulson C, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ. HER-2/neu over-expression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiology, Biomarkers and Prevention 18: 1386-1389 2009.
  72. Bahl S, Roses R, Sharma, A, Koldovsky U, Xu S, Weinstein S, Nisenbaum H, Fox K, Pasha T, Zhang P, Araujo L, Carver J, Czerniecki BJ. Asymptomatic changes in cardiac function can occur in DCIS patients following treatment with HER-2/neu pulsed dendritic cell vaccines. Am Journal Surgery 198:488-494 2009.
  73. Sharma A., Czerniecki BJ, Developing Dendritic Cell Based therapies to Condition Immune Responses to Target Novel Oncogenic Proteins and Stem Cells. Expert Reviews in Pharmacology 2:5, 517-526 2009.
  74. Roses, RE, Kumar R, Alavi A, Czerniecki BJ. The role of lymphatic mapping and sentinel biopsy in the staging of breast cancer. PET Clinics 4:265-276 2009.
  75. Bahl S, Alavi A, Basu S, Czerniecki BJ. The role of PET and PET/CT in the surgical management of breast cancer: A Review. PET Clinics 4: 277-287 2009.
  76. Lee MK, Sharma A, Czerniecki BJ. It’s all in for the HER family in tumorigenesis. Expert Reviews Vaccines 9 (1) 29-34, 2010.
  77. Paustian C, Caspell R, Johnson T, Cohen PA, Shu S, Xu S, Czerniecki BJ, Koski GK. The effect of multiple activation stimuli on the generation of Th1 polarizing DC. Human Immunology 72: 24-31 2011.
  78. Holly Graves and Brian J Czerniecki. Circulating tumor cells in breast cancer patients: An evolving role in patient prognosis and disease progression. Pathology Research International, Vo.l 2011 Article ID 621090, 2011.
  79. Harada S, Mick R, Roses RE, Graves H, Niu H, Sharma A, Schueller J, Nisenbaum H, Czerniecki BJ, Zhang PJ. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. Journal of Surgical Oncology 104:458-465 2011.
  80. Karakousis GC, and Czerniecki BJ. Diagnosis of Melanoma. PET Clinics 6:1-8 2011.
  81. Chiang CLL, Maier DA, Kandalaft LA, Brennan, Evripidis Lanitis AL, Ye Q, Levine BL, Czerniecki BJ, Powell Jr DJ, and Coukos G. Optimizing Parameters for Clinical-scale Production of High IL-12 Secreting Dendritic Cells Pulsed with Oxidized Whole Tumor Cell Lysate. J Translat Med 9(1):198, 2011.
  82. Chiang CLL, Hagenmann AR, Leskowitz R, Mick R , Garrabrant T, Czerniecki BJ, Kandalaft LA, Powell Jr DJ, and Coukos G. Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate are Highly Immunogenic and Elicit Potent Anti-Tumor Responses. PLoS ONE 6(12):e28732, 2011.
  83. Koski G, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, and Czerniecki BJ A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J of Immunotherapy 35: 54-65 2012.
  84. Sharma A, Koldovsky,  Xu S,  Mick R, Roses R, Fitzpatrick, E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang PJ, Koski G, and Czerniecki BJ, HER-2 Pulsed Dendritic Cell Vaccine Can Eliminate HER-2 Expression and Impact DCIS. Cancer 2012 Sep 1;118(17):4354-62. doi: 10.1002/cncr.26734. Epub 2012 Jan 17.
  85. Graves H, Mick R, Sharma A, Lewis R, Roberts S, Fitzpatrick E, Xu S, Zhang P, Czerniecki BJ. High survivin Expression in ductal carcinoma in situ (DCIS): A potential therapeutic target. Current Clinical Cancer Therapy 8: 189-196 2012.
  86. Showalter SL, Grover S, Sharma S, Lin L, Czerniecki BJ. Factors influencing surgical and adjuvant therapy in stage I breast cancer. Annals of Surgical Oncology 20 (4) 1287-94 2013.
  87. Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Dendritic cell-based vaccines: barriers and opportunities. Future Oncology  Oct;8(10):1273-99. doi: 10.2217/fon.12.125, 2012.
  88. Yang RL, Newman AS, Reinke CE, Lin IC, Karakousis GC, Czerniecki BJ, Wu LC, Kelz RR. Racial Disparities in Immediate Breast Reconstruction After Mastectomy: Impact of State and Federal Health Policy Changes. Annals of Surgical Oncology (In Press).
  89. Yang RL, Newman AS, Lin IC, Reinke CE, Karakousis GC, Czerniecki BJ, Wu LC, Kelz RR. The impact of breast cancer legislation on trends in immediate breast reconstruction across insurance groups. Cancer (In Press).
  90. Bartlett EK, Meise C, Bansai N, Fischer J, Czerniecki BJ, Roses R, Fraker DL, Kelz R, Karakousis G. Sartorious flap during inguinal lymphadenectomy for melanoma J Surgical Research (In Press).
  91. Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang PJ, Czerniecki BJ Response to HER-2 pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS.  Annals of Surgical Oncology (In Press).
  92. Chiang C, Kandalaft L, Tanyi J, Hagemann A, Motz G, Svoronos N, Smith L, Montone K, Mantia-Smaldone G, Nisenbaum H, Torogian D, Levine B, Mick R, Kalos M, Czerniecki B, Powel D, and Coukos G. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.  Clinical Cancer Research (In Press).
  93. Cintolo J, Local Immune Response Predicts Survival in Patients with Thick (T4) Melanomas. Annals of Surgical Oncology (In Press).
Research Publications, non-peer reviewed
  1. Witz G. Czerniecki BJ. In vivo inhibition by phorbol esters of oxy radical production by murine peritoneal exudate cells stimulated with phorbol myristate acetate. Annals of the NY Academy of Science 494:294-295, 1987.
  2. Buell JF. Temeck BK. Czerniecki BJ. Lubensky IA. Pass HI. Management of thoracic carcinoid tumors in multiple endocrine neoplasia I population. Contemporary Surgery 49:200-206, 1996.
  3. Mulvany KP. Prabakaran I. Shuwen Xu M. Khorrami C. Menon C. Czerniecki BJ. Fraker DL. Callans LS. Human monocyte-derived dendritic cells transduced with recombinant adenovirus present melanoma antigen gp100 to cytotoxic T lymphocytes in vitro. Surgical Forum 50:311-313, 1999.
Abstracts (last 5 years)
  1. Czerniecki BJ, Koldovsky U, Xu S, Mick R, Nisenbaum H, Orel S, Fox K, Koski G. Combining innate and adaptive immunity for the treatment of breast cancer. International Society of Biological Therapy Meeting, Alexandria VA. November 2005.
  2. Czerniecki BJ, Koldovsky U, Xu S, Xu M, Son G, Nisenbaum H, Zhang P, Mick R, Koski G. Immunoediting Breast Cancer Using HER-2/Neu Pulsed Autologous Dendritic Cell Vaccines. Presented at the Society of University Surgeons, San Diego, CA February 2006.
  3. Xu S, Koldovsky U, Xu, M, Son G, Fitzpatrick E, Wang D, Mick R, Nisenbaum, Zhang P, and Czerniecki BJ. Type-I polarized HER-2/neu pulsed dendritic cell vaccines generate anti-tumor CD8+ T cells despite the presence of antigen specific CD8+ tolerance in patients with early non-invasive breast cancer. American Association for Cancer Research, Washington DC April 2006.
  4. Xu, S, Roses R, Koldovsky U, Xu M, Son G, Czerniecki BJ. Toll-like receptor agonists prime dendritic cells for a second burst of IL-12 upon encountering CD40 ligand. American Association of Cancer Research, Los Angeles, CA. April 2007.
  5. Xu M, Xu S, Roses R, Koldovsky U, Son G, Czerniecki BJ. Toll-like receptor agonist primed dendritic cells overcome immunosuppressive tumor associated molecules. American Association of Cancer Research, Los Angeles, CA April 2007.
  6. Xu S, Roses R, Xu M, Koldovsky U, Czerniecki BJ. Induction of IL-12 and IL-23 through toll like receptors in human monocyte-derived dendritic cells differentially the balance between chronic inflammation and anti-tumor immunity: Implications for cancer vaccines and carcinogenesis American Association of Cancer Research, April 2008.
  7. Xu M, Xu S, Roses R, Koldovsky U, Koski GK, Czerniecki BJ. IL-12 and IL-23 production induced by toll like receptor agonist primed myeloid dendritic cells are differentially regulated by prostaglandin E2. American Association of Immunology, May 2008.
  8. Roses RE, Paulson C, Sharma A, Schueller J, Nisenbaum H, Weinstein S, Fox K, Zhang P, Czerniecki BJ. HER-2/neu expressing DCIS phenotypes and the transition from in situ to invasive breast cancer: implications for breast cancer prevention. San Antonio Breast Cancer Symposium San Antonio, TX December 2008.
  9. Sharma A, Koldovsky U, Xu S, Roses RE, Xu M, Nisenbaum H, Weinstein S, Fox K, Zhang P, Czerniecki BJ. African American Women are capable of developing a clinically significant immune response to HER-2/neu despite decreased HER-2/neu expression in DCIS. Society of Surgical Oncology, March 2009.
  10. Xu S, Koldovsky U, Xu M, Sharma A, Czerniecki BJ. Developing activated innate immune effectors using toll like receptor agonist activated dendritic cells to condition the immune response in the breast. American Association of Cancer Research, Denver CO April 2009.
  11. Bahl S, Koldovsky U, Xu S, Nisenbaum H, Fox K, Zhang P, Araujo L, Carver J, Czerniecki BJ. HER-2/neu pulsed DC1 vaccination in patients with DCIS induces evidence of changes in cardiac function. American Association of Breast Surgeons, San Diego, CA April 2009.
  12. Xu M, Czerniecki BJ. Interactions of TLR agonist activated DC with breast tumor stromal derived molecules, World Cancer Congress, Beijing, China June 2009.
  13. Czerniecki BJ. Targeting molecular pathways for breast cancer prevention using dendritic cell vaccines, NCI Translational Science Meeting, Washington DC July 2011.
  14. Czerniecki BJ. Prevention of estrogen-independent breast cancer using her family targeted dendritic cell vaccines. Omics Vaccine Meeting, Philadelphia, PA Nov 2011.
  15. Yang, R, Lin I, Newman A, Reinke C, Karakousis G, Czerniecki BJ, Wu L, Kelz RR, Pennsylvania Health Policy and its Effects on Racial Disparities in Breast Cancer Reconstruction. Society of Surgical Oncology 2012.
  16. Graves H, Czerniecki BJ. Expression of Survivin Correlates with Histopathologic Grade in Ductal Carcinoma In Situ (DCIS). Society of Surgical Oncology 2012.
  17. Showalter S, Czerniecki BJ Disparities and Trends in the Treatment of Stage I Breast Cancer. Society of Surgical Oncology 2012.
  18. Yang RL, Kelz RR, Graves HL, Nathanson K, Domchek SM, Zhang PJ, Czerniecki BJ. Ductal carcinoma in situ and invasive breast cancer phenotype is highly concordant in BRCA mutation carriers: Implications for prevention. Surgical Forum American College of Surgeons Annual Meeting, Chicago IL October 2012.
  19. Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Fisher C, Zhang PJ, Czerniecki BJ. HER-2-pulsed type I dendritic cells induce T cell and clinical response in early breast cancer patients independent of tumor HER-2 expression levels. Annual Meeting Society of Surgical Oncology, Baltimore, MD March 2013.
  20. Cintolo J, Somasundaram R, Xu S, Gupta M, Czerniecki BJ. Type-I polarized dendritic cell-based vaccine effectively targets BRAFV600E in melanoma. Annual Meeting Society of Surgical Oncology, Baltimore MD March 2013.
  21. Yang RL, Kelz RR, Graves HL, Zhang PJ, Lee K, Nathanson K, Domchek SM, Czerniecki BJ. Defining the association between DCIS and Invasive Breast Cancer found in BRCA1 and BRCA2 mutation carriers. Annual Meeting Society of Surgical Oncology, Baltimore, MD March 2013.
  22. Lee K, Mick R, Graves HL, Zhang PJ, Czerniecki BJ. HER-3 expression in DCIS. Annual Meeting Society of Surgical Oncology, Baltimore, MD March 2013.
  23. Czerniecki BJ. Understanding Dendritic Cell Biology to Realize Their Potential in Immune Based Therapies. Modulation of tumor immunity with hypofractionated and special multi-fraction radiation therapy: Basic mechanisms and clinical implications. NCI Radiation Research Program, Bethesda, MD April 2013.
  24. Czerniecki BJ. Targeting HER-2 expressing breast cancer stem cells in luminal breast cancer using dendritic cell vaccines. 2nd Annual Cancer Immunotherapy Conference Stem Cells and Cancer Immunotherapy, Washington DC, April 2013.
  25. Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang PJ, Czerniecki BJ. Response to HER-2 pulsed vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS American Society of Breast Surgeons Chicago, IL May 2013.
Editorials, Reviews, Chapters & Participation in Committee Reports
  1. Witz G. Czerniecki BJ. Gad SC. Goldstein BD. In vivo stimulation of oxy radicals by mouse skin tumor promoters. In Cerrutti P, Nygaard O, Simic MG (eds): Anticarcinogenesis and Radiation Protection. New York: Plenum Publ. Co., 1987, 199-205.
  2. Cohen PA. Fowler DH. Kim H. White RL. Czerniecki BJ. Carter C. Gress RE. Rosenberg SA. Propagation of mouse and human T cells with defined antigen specificity and function. In: Vaccines against Virally Induced Cancers. New York: Wiley & Sons, 1994 (Ciba Foundation Symposium 187:179-197).
  3. Czerniecki BJ. Bedrosian I. Tumor deprived peptide vaccines for treatment of Melanoma. The Melanoma Letter 15(3), 1997.
  4. Czerniecki BJ. Nguyen H. Glatstein E. Fox K. Treatment of Hodgkin's and Non-Hodgkin's Lymphoma. Chap. 15 in Torosian MH (ed): Integrated Cancer Management: Surgery, Medical Oncology and Radiation Therapy. New York: Marcel-Dekker, 1999, 360-393.
  5. Bedrosian I. Czerniecki BJ. Tumor biology. In Kreisel D, Krupnick AS, Kaiser LR (eds): The Surgical Review. Philadelphia: Lippincott, Williams & Wilkins, 2001, 69-90.
  6. Roses RE, Czerniecki BJ. Mastectomy. In Roses RE, Paulson EC, Kanchawala S. Gowned and Gloved Surgery: Introduction to Common Procedures New York Saunders (In Press).
  7. Roses RE, Czerniecki BJ, The Breast. In PM Porrett, JR Frederick, RE Roses, LR Kaiser (eds): The Surgical Review: Lippincott Williams and Wilkins Philadelphia, 2010; 252-262.
  8. Mittendorf EA, Czerniecki BJ, Peoples GE. Breast Cancer Vaccines In: Kuerer’s Breast Surgical Oncology New York McGraw Hill 2010 937-946.
  9. Kuerer, HM, Pass, HA, Simmons, R, Kurtsman, SH, Cataliotti, L, Newman, LA, Sclafani, LM, Silverstein, MJ, Tafra, L, Audretsch, WP, Jones, RC, Kaufmann, M, Macmillan , RD, Boolbol, SK, Schwartz, GF, Kearney, TJ, Rubio, IT, Deitz, JR, O’Higgins, NJ, Rainsbury, RM, El-Tamer, MB, Gabram-Mendola, SGA, Christiaens, MR, Julian, TB, Jakesz, R, Khakpour, N, Peintinger, F, Degnim, AC, Montogomery, LL, Hansen, NM, Wapnir, IL, Layeequr-Rahman, R, Fenton, AH, Sigurdson, ER, von Smitten, K, Czerniecki, BJ, Ahrendt, GM, Holmes, DR, Margenthaler, JA, Giuliano, AE, Morrow, M. Multidisciplinary training for breast surgical Oncology; In: Kuerer’s Breast Surgical Oncology New York McGraw Hill 2010 xxxi-xli.
  10. Showalter S and Czerniecki BJ Targeting Molecular Pathways for Prevention of High Risk Breast Cancer: A model for Cancer Prevention 2012 (PDF) (InTech)
  11. Yang RL, Kelz RR, Czerniecki BJ. Immediate reconstruction following nipple-sparing mastectomy: one option for young breast cancer patients with early stage disease. J Thoracic Dis Jun 06 doi: 10.3978/j.issn.2072-1439.2013.06.07 2013.
Alternative Media
  1. Penniesinaction.org Video presentation DC1 vaccines
    http://www.cbsnews.com/8301-18563_162-57326411/theres-hope-for-a-breast-cancer-vaccine/?tag=contentBody;cbsCarousel
Patents
  1. University of Pennsylvania Health System and Czerniecki BJ. Method for isolating dendritic cells: Preparing and activating dendritic cell rich antigen presenting cells from human peripheral blood. U.S. Patent awarded January 1997.
  2. Czerniecki BJ. Tumor reactive cells: Their proliferation and use in adoptive cellular therapy: Determinations of lymph nodes enriched in CD4+ T-helper lymphocytes and their proliferation for use in adoptive immunotherapy. U.S. Patent awarded April 1998.
  3. Czerniecki BJ. Method for increasing the antigen presenting ability of leukemia cells. US patent awarded March 2002.
  4. Czerniecki BJ, “System and Method of Preparing and Storing Activated Mature Dendritic Cells” Patent filed US Patent Number 61/313,984 March, 2010.
  5. Czerniecki BJ, “Creating hyperpolarized type I dendritic cells using combinations of calcium signaling agents and toll like receptors” Patent in preparation.

Dr. Brian Czerniecki

 
footer Terms of Use Legal Disclaimer Site Map Contact Us Financial Assistance About Penn Medicine Privacy Statement
penn medicine